ArticleMultiple sclerosis journal - experimental, translational and clinical

A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse.

Benjamin M Greenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.